Calcium × phosphate product · patients with bone disease in children with chronic kidney disease
1 finding from 1 review
Calcium mg/dL · patients with bone disease in children with chronic kidney disease
1 finding from 1 review
Serum phosphorus · patients with bone disease in children with chronic kidney disease
1 finding from 1 review
Change in height · patients with bone disease in children with chronic kidney disease
1 finding from 1 review
Augmentation procedure (partial) failure · Patients with vertically deficient posterior/anterior mandibular ridges needing implants
Vertical distraction osteogenesis showed no clear difference in augmentation procedure (partial) failure compared with autogenous onlay bone graft (mandibular ramus); GRADE not reported.
1 finding from 1 review
Complications · Patients with vertically deficient posterior/anterior mandibular ridges needing implants
Vertical distraction osteogenesis showed no clear difference in complications compared with autogenous inlay bone graft (iliac crest); GRADE not reported.
1 finding from 1 review
Complication at augmentation + donor site · Patients with vertically deficient posterior/anterior mandibular ridges needing implants
Vertical distraction osteogenesis showed no clear difference in complication at augmented + donor site compared with autogenous onlay bone graft (mandibular ramus); GRADE not reported.
1 finding from 1 review
Complication at augmentation + donor site · Patients with vertically deficient posterior/anterior mandibular ridges needing implants
Vertical distraction osteogenesis showed no clear difference in complication at augmentation + donor site compared with vertical GBR with non-resorbable barriers + particulate autogenous…; GRADE not reported.
1 finding from 1 review
Intervention not reported
Pegylated interferon beta‐1a (Direct evidence; 1 RCT; 1512 participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…
The intervention may leads to lower pegylated interferon beta‐1a (Direct evidence; 1 RCT; 1512… (low certainty).
1 finding from 1 review
Intervention not reported
Natalizumab (Direct evidence; 1 RCT; 942 participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…
The intervention leads to lower natalizumab (Direct evidence; 1 RCT; 942 participants) (high certainty).
1 finding from 1 review
Intervention not reported
Teriflunomide (Direct evidence; 1 RCT; 1169 participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…
The intervention may leads to lower teriflunomide (Direct evidence; 1 RCT; 1169 participants) (low certainty).
1 finding from 1 review
Intervention not reported
Placebo · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Alemtuzumab No direct evidence · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention leads to lower alemtuzumab No direct evidence (high certainty).
1 finding from 1 review
RR 0.57 [0.47, 0.68]
Studies not reported
High
Intervention not reported
Azathioprine (Direct evidence; 1 RCT; 59 participants) · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
It is very uncertain whether the intervention changes azathioprine (Direct evidence; 1 RCT; 59 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Cladribine (Direct evidence; 1 RCT; 1326 participants) · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention leads to lower cladribine (Direct evidence; 1 RCT; 1326 participants) (high certainty).
1 finding from 1 review
Intervention not reported
Dimethylfumarate (Direct evidence; 2 RCTs; 2307 participants) · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention probably leads to lower dimethylfumarate (Direct evidence; 2 RCTs; 2307 participants) (moderate certainty).
1 finding from 1 review
Intervention not reported
Azathioprine (Direct evidence; 1 RCT; 59 participants) · Patients with RRMS Interventions: Azathioprine, daclizumab, fingolimod, glatiramer acetate, Immunoglobulins, interferon beta 1a ‐1b,…
It is very uncertain whether the intervention changes azathioprine (Direct evidence; 1 RCT; 59 participants) (very low certainty).
1 finding from 1 review
Intervention not reported
Fingolimod (Direct evidence; 2 RCTs; 2355 participants) · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention probably leads to lower fingolimod (Direct evidence; 2 RCTs; 2355 participants) (moderate certainty).
1 finding from 1 review
Intervention not reported
Glatiramer acetate (Direct evidence; 3 RCsT; 1014 participants) · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention probably leads to lower glatiramer acetate (Direct evidence; 3 RCsT; 1014 participants) (moderate certainty).
1 finding from 1 review
RR 0.84 [0.76, 0.93]
3 participants
Moderate
Intervention not reported
Immunoglobulins (Direct evidence; 2 RCTs; 192 participants) · Patients with RRMS Interventions: alemtuzumab, azathriopine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…
The intervention may leads to lower immunoglobulins (Direct evidence; 2 RCTs; 192 participants) (low certainty).
1 finding from 1 review